Published in Circ Cardiovasc Imaging on November 08, 2013
Letter by Schuchlenz regarding article, "Transesophageal echocardiography in cryptogenic stroke and patent foramen ovale analysis of putative high-risk features from the risk of paradoxical embolism database". Circ Cardiovasc Imaging (2014) 0.95
Controversies in cardioembolic stroke. Curr Treat Options Cardiovasc Med (2015) 0.90
Embolic Strokes of Unknown Source and Cryptogenic Stroke: Implications in Clinical Practice. Front Neurol (2016) 0.78
The RoPE Score and Right-to-Left Shunt Severity by Transcranial Doppler in the CODICIA Study. Cerebrovasc Dis (2015) 0.77
Endocardial Device Leads in Patients with Patent Foramen Ovale: Echocardiographic Correlates of Stroke/TIA and Mortality. Pacing Clin Electrophysiol (2016) 0.75
4D flow MRI assessment of right atrial flow patterns in the normal heart - influence of caval vein arrangement and implications for the patent foramen ovale. PLoS One (2017) 0.75
Response to letter regarding article, "Transesophageal echocardiography in cryptogenic stroke and patent foramen ovale analysis of putative high-risk features from the risk of paradoxical embolism database". Circ Cardiovasc Imaging (2014) 0.75
Ischemic stroke subtypes and migraine with visual aura in the ARIC study. Neurology (2016) 0.75
PFO or UFO: how good is transesophageal echocardiography in identifying patent foramen ovale as the cause of a cryptogenic stroke? Circ Cardiovasc Imaging (2014) 0.75
Prevention of recurrent stroke in patients with patent foramen ovale. Neurol Clin (2015) 0.75
Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke (1993) 29.81
Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med (2012) 8.19
Prevalence of patent foramen ovale in patients with stroke. N Engl J Med (1988) 5.94
Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med (2007) 5.65
Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA (2007) 5.60
Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med (2001) 5.10
Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation (2002) 4.69
Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med (2013) 4.62
Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke (2009) 4.14
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials (2010) 3.45
Frequency of atrial septal aneurysms in patients with cerebral ischemic events. Circulation (1999) 2.71
Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study. Stroke (2008) 2.60
Patent foramen ovale and stroke. Circulation (2005) 2.34
An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology (2013) 2.26
Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. J Am Coll Cardiol (2007) 2.15
The association between the diameter of a patent foramen ovale and the risk of embolic cerebrovascular events. Am J Med (2000) 1.91
Aortic atherosclerosis, hypercoagulability, and stroke the APRIS (Aortic Plaque and Risk of Ischemic Stroke) study. J Am Coll Cardiol (2008) 1.85
Is patent foramen ovale a modifiable risk factor for stroke recurrence? Stroke (2010) 1.83
Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence. Stroke (2011) 1.74
Morphological and functional characteristics of patent foramen ovale and their embolic implications. Stroke (2000) 1.66
Recurrent stroke on imaging and presumed paradoxical embolism: a cross-sectional analysis. Neurology (2012) 1.63
Outcome of patients with cryptogenic stroke and patent foramen ovale. J Neurol Neurosurg Psychiatry (2002) 1.63
Patent foramen ovale: echocardiographic detection and clinical relevance in stroke. J Am Soc Echocardiogr (2010) 1.60
Patent foramen ovale: current pathology, pathophysiology, and clinical status. J Am Coll Cardiol (2005) 1.60
Atrial anatomy in non-cardioembolic stroke patients: effect of medical therapy. J Am Coll Cardiol (2003) 1.58
Patent foramen ovale size and embolic brain imaging findings among patients with ischemic stroke. Stroke (1998) 1.52
Prevalence of atrial septal abnormalities in older patients with cryptogenic ischemic stroke or transient ischemic attack. Clin Neurol Neurosurg (2008) 1.51
Persisting eustachian valve in adults: relation to patent foramen ovale and cerebrovascular events. J Am Soc Echocardiogr (2004) 1.46
Atrial septal aneurysm: a new classification in two hundred five adults. J Am Soc Echocardiogr (1997) 1.40
Characteristics of patent foramen ovale associated with cryptogenic stroke. A biplane transesophageal echocardiographic study. Stroke (1994) 1.34
Current management and risk of recurrent stroke in cerebrovascular patients with right-to-left cardiac shunt. Cerebrovasc Dis (2009) 1.34
The risk of paradoxical embolism (RoPE) study: initial description of the completed database. Int J Stroke (2012) 1.32
Morphology of the patent foramen ovale in asymptomatic versus symptomatic (stroke or transient ischemic attack) patients. Am J Cardiol (2008) 1.12
Comparison of transcranial contrast Doppler sonography and transesophageal contrast echocardiography for the detection of patent foramen ovale in young stroke patients. Am J Cardiol (1994) 1.12
Recurrent stroke/TIA in cryptogenic stroke patients with patent foramen ovale. Can J Neurol Sci (2007) 1.06
Patent foramen ovale and brain infarct. Echocardiographic predictors, recurrence, and prevention. Stroke (1994) 0.97
Patent foramen ovale in patients with cerebral infarction. A transesophageal echocardiographic study. Arch Neurol (1997) 0.92
Feasibility and clinical utility of transesophageal echocardiography in the acute phase of cerebral ischemia. Am J Cardiol (2010) 0.92
Patent foramen ovale: the known and the to be known. J Am Coll Cardiol (2012) 0.92
Permanent right-to-left shunt is the key factor in managing patent foramen ovale. J Am Coll Cardiol (2011) 0.91
Interobserver and intraobserver variability in detection of patent foramen ovale and atrial septal aneurysm with transesophageal echocardiography. J Am Soc Echocardiogr (2002) 0.91
Association between anatomic features of atrial septal abnormalities obtained by omni-plane transesophageal echocardiography and stroke recurrence in cryptogenic stroke patients with patent foramen ovale. Am J Cardiol (2010) 0.88
Patent foramen ovale: anatomy versus pathophysiology--which determines stroke risk? J Am Soc Echocardiogr (2003) 0.82
Prevalence of patent foramen ovale determined by transesophageal echocardiography in patients with cryptogenic stroke aged 55 years or older. Same as younger patients? Rev Esp Cardiol (2010) 0.80
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med (2014) 12.79
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet (2009) 11.81
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25
Major lipids, apolipoproteins, and risk of vascular disease. JAMA (2009) 10.58
Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med (2015) 9.58
Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet (2011) 9.07
Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med (2012) 8.19
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet (2007) 7.61
Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med (2013) 7.00
Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med (2015) 6.96
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (2007) 6.77
Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA (2009) 5.63
One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA (2007) 5.61
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet (2010) 5.31
Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke (2009) 5.28
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA (2006) 5.00
Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 4.94
Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis. BMJ (2011) 4.71
Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation (2002) 4.69
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med (2013) 4.62
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet (2016) 4.49
Therapy of basilar artery occlusion: a systematic analysis comparing intra-arterial and intravenous thrombolysis. Stroke (2006) 4.47
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet (2010) 4.46
Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA (2008) 4.21
Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke (2009) 4.14
Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the Northern Manhattan Study. Circulation (2005) 4.08
Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. Lancet (2010) 4.07
Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol (2005) 4.05
Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA (2007) 4.03
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med (2015) 3.75
Myocardial perfusion imaging for evaluation and triage of patients with suspected acute cardiac ischemia: a randomized controlled trial. JAMA (2002) 3.65
Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ (2011) 3.65
Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke (2004) 3.60
Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med (2005) 3.60
An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2013) 3.60
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation (2007) 3.40
Treatment and outcomes of acute basilar artery occlusion in the Basilar Artery International Cooperation Study (BASICS): a prospective registry study. Lancet Neurol (2009) 3.36
Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke (2008) 3.21
Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke (2003) 3.18
Coronary collateral function long after drug-eluting stent implantation. J Am Coll Cardiol (2006) 3.07
Incidence and outcomes of ventilator-associated tracheobronchitis and pneumonia. Am J Med (2013) 3.03
Genetic associations with valvular calcification and aortic stenosis. N Engl J Med (2013) 3.02
Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation (2003) 2.97
Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res (2008) 2.88
Addition of brain and carotid imaging to the ABCD² score to identify patients at early risk of stroke after transient ischaemic attack: a multicentre observational study. Lancet Neurol (2010) 2.87
Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet (2009) 2.81
Blood pressure and vessel recanalization in the first hours after ischemic stroke. Stroke (2005) 2.78
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77
Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol (2008) 2.77
Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis. Eur Urol (2008) 2.77
Ankle-brachial index and subclinical cardiac and carotid disease: the multi-ethnic study of atherosclerosis. Am J Epidemiol (2005) 2.75
Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet (2012) 2.69
Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. Catheter Cardiovasc Interv (2011) 2.67
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke (2007) 2.55
Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension. J Hypertens (2014) 2.54
Vertebral artery dissection: presenting findings and predictors of outcome. Stroke (2006) 2.52
Ideal cardiovascular health predicts lower risks of myocardial infarction, stroke, and vascular death across whites, blacks, and hispanics: the northern Manhattan study. Circulation (2012) 2.48
Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol (2005) 2.47
Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation (2009) 2.47
The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke (2006) 2.43
Aortic arch plaques and risk of recurrent stroke and death. Circulation (2009) 2.40
Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest (2003) 2.39
Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke: a systematic review and meta-analysis. Stroke (2005) 2.38
Predicting six-month mortality for patients who are on maintenance hemodialysis. Clin J Am Soc Nephrol (2009) 2.38
Traditional risk factors are not major contributors to the variance in carotid intima-media thickness. Stroke (2013) 2.34
Relation of plasma glucose and endothelial function in a population-based multiethnic sample of subjects without diabetes mellitus. Am J Cardiol (2005) 2.34
Long-term functional recovery after first ischemic stroke: the Northern Manhattan Study. Stroke (2009) 2.33
Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol (2004) 2.30
Risk of myocardial infarction or vascular death after first ischemic stroke: the Northern Manhattan Study. Stroke (2007) 2.30
Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol (2006) 2.27
Index event bias as an explanation for the paradoxes of recurrence risk research. JAMA (2011) 2.27
An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology (2013) 2.26